Kevin Young - Gilead Sciences COO

GILD Stock  USD 73.01  0.60  0.83%   

COO

Mr. Kevin B. Young is the Chief Operating Officer of Gilead Sciences, Inc. He served as Executive Vice President of Commercial Operations from 2004 through 2014, and from 2014 to 2016 served as senior advisor to the company. Prior to Gilead, Mr. Young spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. During his 12 years at Amgen, he held a number of positions in Europe and the United States, including Head of the U.S. Inflammation Business Unit, leading the relaunch of Enbrel following the acquisition of Immunex Corporationrationration. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool and Nottingham, England. In 2011 he was appointed a Commander of The British Empire, one of Great Britains highest civilian honors, in recognition of his services to the healthcare and pharmaceutical industries. since 2016.
Age 58
Tenure 8 years
Address 333 Lakeside Drive, Foster City, CA, United States, 94404
Phone650 574 3000
Webhttps://www.gilead.com

Kevin Young Latest Insider Activity

Tracking and analyzing the buying and selling activities of Kevin Young against Gilead Sciences stock is an integral part of due diligence when investing in Gilead Sciences. Kevin Young insider activity provides valuable insight into whether Gilead Sciences is net buyers or sellers over its current business cycle. Note, Gilead Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Gilead Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Gilead Sciences Management Efficiency

The company has return on total asset (ROA) of 0.0978 % which means that it generated a profit of $0.0978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2554 %, meaning that it created $0.2554 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.19. The current year's Return On Assets is expected to grow to 0.1. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.9 B, whereas Total Current Assets are forecasted to decline to about 10.8 B.
The company currently holds 24.99 B in liabilities with Debt to Equity (D/E) ratio of 1.3, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 1.4, which is within standard range for the sector. Debt can assist Gilead Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Gilead Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gilead Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gilead to invest in growth at high rates of return. When we think about Gilead Sciences' use of debt, we should always consider it together with cash and equity.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 14400 people. Gilead Sciences (GILD) is traded on NASDAQ Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA, United States, 94404 and employs 18,000 people. Gilead Sciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Gilead Sciences Leadership Team

Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kathleen Watson, Executive Vice President - Human Resources
John McHutchison, Executive Vice President - Clinical Research
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations
John Martin, Chairman and CEO
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Michael Quigley, VP Biology
Linda Higgins, Innovation Research
Gayle Wilson, Independent Director
Daniel ODay, Chairman of the Board, CEO
Jacqueline Barton, Director
Brett Pletcher, Executive VP and General Counsel
William Lee, Executive Vice President - Research
Deborah Telman, General Affairs
John Madigan, Independent Director
Martin Silverstein, Executive Vice President - Strategy
Kevin Lofton, Independent Director
Jacquie CFA, Vice Relations
Paul Carter, Executive Vice President - Commercial Operations
Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary
Diana Brainard, Senior Vice President HIV and Emerging Viral Infections
Flavius MD, Executive Research
Carla Hills, Independent Director
John Cogan, Lead Independent Director
Sandra Patterson, Corporate VP
John Milligan, Pres and COO
Nicholas Moore, Independent Director
James Meyers, Executive Vice President - Worldwide Commercial Operations
Katie Watson, Executive Vice President of Human Resources
Kelly Kramer, Director
Johanna Mercier, Chief Commercial Officer
Jyoti Mehra, Executive Vice President of Human Resources
Laura Hamill, Executive Vice President - Worldwide Commercial Operations
Robin Washington, CFO and Executive VP
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD
Per WoldOlsen, Independent Director
Harish Manwani, Director
Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing
Kevin Young, COO
Etienne Davignon, Independent Director
Richard Whitley, Independent Director
Diane Wilfong, Corp VP
Rudolf Ertl, Canada, Australia

Gilead Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Gilead Sciences Investors Sentiment

The influence of Gilead Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Gilead. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Gilead Sciences.

Gilead Sciences Implied Volatility

    
  24.93  
Gilead Sciences' implied volatility exposes the market's sentiment of Gilead Sciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Gilead Sciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Gilead Sciences stock will not fluctuate a lot when Gilead Sciences' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gilead Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gilead Sciences' short interest history, or implied volatility extrapolated from Gilead Sciences options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Transaction History
View history of all your transactions and understand their impact on performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Global Correlations
Find global opportunities by holding instruments from different markets
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.